UNSPSC 51433908: Barnidipine

This classification denotes a calcium channel blocker with the molecular formula C27H29N3O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2VBY96ASWJ, chemically known as (+)-(3s,4s)-1-benzyl-3-pyrrolidinyl methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate but generally known as barnidipine, which bears US NIH Compound Identifier 65884. Barnidipine most often comes in base and hydrochloride forms.

UNSPSC 51433908 Barnidipine, a Commodity code, represents emergency and hospital medications that state and local governments—particularly fire rescue departments and health agencies—procure for Advanced Life Support (ALS) protocols and pharmacy benefit programs. The code encompasses specific pharmaceutical products supplied through established wholesale distribution channels to support emergency medical services and health benefit administration across multiple jurisdictions. State and local buyers under this code include municipal fire rescue departments, state health and human services commissions, and multistate cooperative purchasing alliances that aggregate demand across participating government entities. The scope of work includes sourcing pharmaceutical products with verified National Drug Codes, managing inventory with expiration-date compliance, arranging rapid delivery and product replacement, and maintaining FDA and Drug Supply Chain Security Act (DSCSA) compliance documentation including Safety Data Sheets and cGMP certifications.

Recent activity spans Florida, Texas, and Minnesota through a mix of issuing bodies. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications on April 24, 2026, with response due April 8, 2026, requiring supply of four medication line items (Labetalol HCI, Epinephrine, Adenosine, and Diltiazem) for Tampa Fire Rescue with an estimated contract value of $40,000 and a one-year term with two optional renewals plus three 30-day unilateral extensions; the solicitation included a 5 percent bid discount for Small Local Business Enterprise participation. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, with response deadline March 26, 2026, for generic multi-source pharmaceuticals and OTC products to be distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, with contract effectiveness July 1, 2026, and awards extended to Oregon participants.